Management and therapy of vasovagal syncope: A review

Table 1 Midodrine: randomized placebo-controlled trials

Author, year	n	Follow-up period	Endpoint	P
Ward et al[57], 1998	16	1 mo	TT	0.01
Perez-Lugones et al[58], 2001	61	6 mo	Syncope recurrence	< 0.01
Kaufmann et al[59], 2002	12	1 wk	TT	< 0.02
Qingyou et al[60], 2006	26	42 mo	TT	< 0.05

TT: Head-up tilt table test.

Table 2 Selective serotonin reuptake inhibitors: randomized placebo-controlled trials

Author, year	n	Drug	Follow-up period	Endpoint	P
Theodorakis et al[63], 2006	96	Fluoxetine	6 mo	Time to vasovagal episode	< 0.05
				Well-being	0.01
				Syncope episodes	NS
Di Girolamo et al[62], 1999	68	Paroxetine	6 mo	TT	< 0.001
				Syncope recurrence	0.001

TT: Head-up tilt table test; NS: Not significant.

Table 3 Pacemaker-therapy: randomized trials

Author, year	Trial	n	Design	Follow-up period (yr)	Endpoint	P
Conolly et al[65], 1999	VPS I	54	No placebo	1	Syncope recurrence	< 0.001
Sutton et al[66], 2000	VASIS	42	No placebo	3.7	Syncope recurrence	< 0.001
Ammirati et al[67], 2001	SYDIT	93	No placebo	1.5	Syncope recurrence	0.004
Conolly et al[68], 2003	VPS II	100	Placebo	0.5	Syncope recurrence	NS
Raviele et al[69], 2004	SYNPACE	29	Placebo	2 yr	Syncope recurrence	NS

NS: Not significant.